The demand for obesity drugs in India surges as Eli Lilly and Novo Nordisk vie for market share. Meanwhile, President Trump ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

The man had 'tried everything' before Mounjaro gave him a 'life-saving' change, leading to an incredible nine stone weight ...

The demand for obesity drugs in India is surging as Eli Lilly and Novo Nordisk compete. A Pakistani startup sends prosthetics ...

Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss drug. Available in six dosages, Mounjaro helps manage type 2 diabetes ...

The stocks listed here each increased their dividend payments by more than 10% recently. When you think of a great dividend ...

Eli Lilly’s Mounjaro has sold over 81,570 units in India, with cumulative sales of ₹ 23.94 crore by May 2025, according to pharma intelligence platform Pharmarack.

Eli Lilly and Company (India) has received regulatory approval for its diabetes and weightloss drug Mounjaro (tirzepatide), in a KwikPen device. The US-based company had launched its product in ...

NEW DELHI: India’s drug regulator has approved Eli Lilly and Company’s diabetes and obesity drug Mounjaro in a KwikPen presentation, the pharmaceutical giant announced on Thursday. The Central ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.